S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Sera Prognostics (SERA) Stock Price, News & Analysis

$9.75
-0.04 (-0.41%)
(As of 04:38 PM ET)
Today's Range
$9.51
$9.86
50-Day Range
$8.47
$11.25
52-Week Range
$1.52
$11.32
Volume
63,388 shs
Average Volume
234,233 shs
Market Capitalization
$316.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
71.8% Downside
$2.75 Price Target
Short Interest
Healthy
1.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.60mentions of Sera Prognostics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.26 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.83 out of 5 stars

Medical Sector

828th out of 918 stocks

Medical Laboratories Industry

18th out of 20 stocks

SERA stock logo

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

SERA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sera Prognostics Inc Class A
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sera Prognostics: Q4 Earnings Insights
Sera Prognostics's Earnings Outlook
See More Headlines
Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/19/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:SERA
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$2.75
Low Stock Price Target
$2.75
Potential Upside/Downside
-71.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-36,240,000.00
Net Margins
-11,843.79%
Pretax Margin
-11,843.79%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$2.21 per share

Miscellaneous

Free Float
27,368,000
Market Cap
$317.49 million
Optionable
Not Optionable
Beta
1.49
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Evguenia Lindgardt M.B.A. (Age 50)
    President, CEO & Director
    Comp: $37.5k
  • Dr. Gregory C. Critchfield M.D. (Age 71)
    M.S., Executive Director
    Comp: $790.74k
  • Dr. Steven W. Graves
    Co-Founder and Co-Chairman of The Scientific Advisory Board
  • Dr. M. Sean Esplin M.D.
    Co-Founder and Co-Chairman of Scientific Advisory Board
  • Mr. Austin Aerts
    Chief Financial Officer??
  • Dr. John J. Boniface Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $386.69k
  • Mr. Robert G. Harrison (Age 58)
    Chief Information Officer
    Comp: $384.18k
  • Mr. Benjamin G. Jackson J.D. (Age 45)
    General Counsel
    Comp: $410.75k
  • Dr. Paul Kearney Ph.D. (Age 56)
    Chief Data Officer

SERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SERA shares.
View SERA analyst ratings
or view top-rated stocks.

What is Sera Prognostics' stock price target for 2024?

2 brokers have issued 1 year price objectives for Sera Prognostics' shares. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's stock price to reach $2.75 in the next year. This suggests that the stock has a possible downside of 71.8%.
View analysts price targets for SERA
or view top-rated stocks among Wall Street analysts.

How have SERA shares performed in 2024?

Sera Prognostics' stock was trading at $5.98 at the beginning of 2024. Since then, SERA shares have increased by 62.9% and is now trading at $9.74.
View the best growth stocks for 2024 here
.

Are investors shorting Sera Prognostics?

Sera Prognostics saw a increase in short interest in March. As of March 31st, there was short interest totaling 198,600 shares, an increase of 71.5% from the March 15th total of 115,800 shares. Based on an average trading volume of 245,400 shares, the short-interest ratio is currently 0.8 days. Currently, 1.2% of the shares of the company are short sold.
View Sera Prognostics' Short Interest
.

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SERA earnings forecast
.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) announced its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 45.74%.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.06%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt.
View institutional ownership trends
.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SERA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners